synthetic glycoconjugate Candida albicans vaccine (NovaDigm)

N/A

Report date: 2026/01/23 11:09:30

Base Information

Drug Namesynthetic glycoconjugate Candida albicans vaccine (NovaDigm)

Drug Alias Namesynthetic glycoconjugate Candida albicans vaccine (University of Alberta)synthetic glycoconjugate Candida albicans vaccine (University of Alberta/Alberta Glycomics Centre)

ClassificationVaccines > Biological material > Toxoid vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsCandida Albicans Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Alberta

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlycomics Institute of Alberta University Of Alberta Novadigm Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsCandida Albicans Infections

Other Information

ATC CodeN/A